Rational Combinations to Enhance Efficacy of Bispecific T Cell Engagers (BiTEs) in Solid Tumors
Time: 11:40 am
day: Day One
Details:
• Recent progress with development of bispecific T-cell engager (BiTE) molecules in solid tumors
• Strategies to improve response rate and durability
• Preclinical data for the DLL3-targeted BiTE molecule (IMDELLTRA™ / tarlatamab) in combination with standard of care and Immune check point inhibitors, and translation to the clinic
